The “STRONG” Consortium has been established to study Neovascular Glaucoma secondary to ischemic Central Retinal Vein Occlusion (i-CRVO), a rare eye disease. Aganirsen antisense oligonucleotide topical eye emulsion will be used for “STRONG Study”, the first-ever randomized controlled multicentre study for Neovascular Glaucoma secondary to i-CRVO. The STRONG study will also provide new insights into the natural course of the disease and its risk factors through two sub-studies, benefitting from one of the largest patient cohorts ever. Finally, STRONG will yield novel image analysis tools in development in the context of this study.
The consortium comprises some of Europe’s leading Eye Hospitals from the European Vision Institute Clinical Research Network (EVICR.net): The Department of Ophthalmology of the University Medical Centre of the Johannes Gutenberg-University Mainz, Germany; AIBILI – Association for Innovation and Biomedical Research on Light and Image, Coimbra, Portugal; The University Hospital of Cologne, Germany; and Moorfields Eye Hospital, London, UK; together with Gene Signal, a Swiss-based biotechnology company who discovered and developed the novel eye-emulsion therapy Aganirsen ; TechnoSTAT, Israel, responsible for statistics; AMATSI, France, responsible for pharmaceutical development and manufacturing and Bundesverband Glaukom-Selbsthilfe e.V., Germany, a patient advocacy group.
The “STRONG” Consortium has been awarded a European Union grant in line with the EU Health Directorate’s research initiative, the 7th Framework Programme, known as FP7.
The award was granted to the “European Consortium for the Study of a Topical Treatment of Neovascular Glaucoma” (The “STRONG Study”) within the category for “Preclinical and/or clinical development of substances with a clear potential as orphan drugs”.